It establishes p16 as a reliable, highly sensitive surrogate marker for inference of CDKN2A homozygous deletion in gliomas, with a recommended p16 expression score of ≤ 5% for confirming and > 20% for excluding CDKN2A homozygous loss. This evidence concerns the gene CDKN2A and glioma.